Nezafati Pouya, Uchime Chimezi, Yadav Sumit
Department of Cardiothoracic Surgery, Liverpool Hospital, New South Wales Health, Sydney, Australia.
Department of Cardiothoracic Surgery, Townsville University Hospital, Queensland Health, Townsville, QLD, 4814, Australia.
J Cardiothorac Surg. 2025 Aug 9;20(1):331. doi: 10.1186/s13019-025-03369-y.
The Perceval Sutureless prosthesis can increase the effective orifice area (EOA) and reduce the chance of prosthesis-patient mismatch (PPM). This report presents three patients with challenging degenerated bioprosthetic valves undergoing redo aortic valve replacement (rAVR) using the Perceval (LivaNova, London, UK) prosthesis from a cohort of more than 300 performed cases and a review of the literature on the management of challenging degenerated valves.
Case 1: Degenerated 23 mm Trifecta with the valve cage densely adherent to the annulus. Cage with sewing ring were excised and annulus sized to a large Perceval valve. Case 2: Degenerated 29 mm Epic from a Bentall's procedure. Calcified and rigid prosthetic leaflets as well as stent posts were excised and XL Perceval implanted. Case 3: Degenerated 27 mm Epic with signs of endocarditis from a history of Bentall's procedure. Three calcified leaflets of the Epic valve were completely excised. The orifice accepted a medium Perceval.
The total Cardiopulmonary Bypass (CPB) and aortic cross clamp (ACC) times (in minutes) were 99.76, 117.68 and 143.99 in Cases 1, 2 and 3, respectively. Moreover, post-implantation transesophageal echocardiogram (TOE) demonstrated a well-seated valve, no paravalvular leak in all cases and a peak gradient of 12.7 mmHg, 14.8 mmHg and 17.7 mmHg in Cases 1, 2 and 3, respectively.
The Perceval prosthesis is an excellent choice for rAVR, as it can safely simplify challenging cases at risk of PPM and is an excellent valve-in-valve alternative to degenerated or infected Bentall valves with patent graft. The Perceval prosthesis can be well seated on the different structures of a degenerated bioprosthetic valve.
Perceval无缝合人工瓣膜可增加有效瓣口面积(EOA)并降低人工瓣膜与患者不匹配(PPM)的几率。本报告介绍了3例使用Perceval(英国伦敦LivaNova公司)人工瓣膜进行再次主动脉瓣置换术(rAVR)的具有挑战性的退化生物瓣膜患者,该队列超过300例手术病例,并对有关具有挑战性的退化瓣膜管理的文献进行了综述。
病例1:23毫米Trifecta瓣膜退化,瓣膜笼与瓣环紧密粘连。切除带有缝合环的瓣膜笼,并将瓣环尺寸调整为适合大型Perceval瓣膜。病例2:来自Bentall手术的29毫米Epic瓣膜退化。切除钙化且僵硬的人工瓣膜小叶以及支架柱,并植入XL Perceval瓣膜。病例3:来自Bentall手术史且有感染性心内膜炎迹象的27毫米Epic瓣膜退化。完全切除Epic瓣膜的三个钙化小叶。瓣口适合中型Perceval瓣膜。
病例1、2和3的体外循环(CPB)和主动脉阻断(ACC)总时间(分钟)分别为99.76、117.68和143.99。此外,植入后经食管超声心动图(TOE)显示瓣膜就位良好,所有病例均无瓣周漏,病例1、2和3的峰值梯度分别为12.7 mmHg、14.8 mmHg和17.7 mmHg。
Perceval人工瓣膜是rAVR的极佳选择,因为它可以安全地简化有PPM风险的具有挑战性的病例,并且是退化或感染的带专利移植物的Bentall瓣膜的极佳瓣中瓣替代方案。Perceval人工瓣膜可以很好地安置在退化生物瓣膜的不同结构上。